> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Texas Bill Could Expand ‘Off-Label’ Drug Use
- URL: https://www.fdaweb.com/texas-bill-could-expand-off-label-drug-use/
- Published: 2021-04-22T12:00:00.000Z
- Updated: 2026-09-14T16:56:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149163

A Texas state senator has introduced the “Truth in Medicine Act” to allow drug companies, doctors, and patients to freely discuss medical options, including potentially life-saving medications that have not been approved by FDA. Sen. **Paul Bettencourt** (R) told [*State of Reform*](https://stateofreform.com/featured/2021/04/texas-truth-in-medicine-act-could-broaden-off-label-use-of-medications/?ref=fdaweb.com) that while providers are legally permitted to prescribe medications for off-label purposes, the drug manufacturer is prohibited from sharing information or promoting any use of the drug other than the FDA-approved indication.

Under the [bill](https://capitol.texas.gov/tlodocs/87R/billtext/pdf/SB01820I.pdf?ref=fdaweb.com#navpanes=0), the state would be prohibited from disciplining or removing the license of providers and companies who share off-label information.

“SB 1820 is a bill about medical freedom,” Bettencourt said. “This is just a common-sense bill to get ahead of what everybody’s already using, which is off-label uses for existing medications that have already passed all four levels of screening for FDA.”